Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?

Sponsor
Case Comprehensive Cancer Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05720338
Collaborator
(none)
234
2
49

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to analyze if intraperitoneal drainage is necessary following distal pancreatectomy. This study aims to determine whether the omission of routine intraperitoneal drainage in the setting of reinforced staple technology is non-inferior to routine intraperitoneal drainage with respect to a composite post-operative complications of Grade B or C Postoperative pancreatic fistula (POPF), readmission, or organ space surgical site infection following a distal pancreatectomy.

Condition or Disease Intervention/Treatment Phase
  • Device: 19 French Blake Drain
Phase 3

Detailed Description

Pancreatic resections are commonly performed across the United States, yet still represent one of the most morbid abdominal operations in the country, with postoperative mortality as high as 7.7%. Distal pancreatectomy (DP) represents one of the most common approaches to pancreatic resection and is typically used for tumors of the pancreatic body or tail. This operation is known to have a high historic morbidity, with reports of overall morbidity between 12-52%. Common complications include intraabdominal abscess and surgical site infection. Postoperative pancreatic fistula (POPF) represents the most common complication following partial pancreatic resection, with rates reported with rates as high as 30% in multiple large retrospective studies. Multiple strategies to prevent postoperative pancreatic leak following distal pancreatectomy have been studied. One of the outstanding questions that remains is regarding the need for routine intraperitoneal drainage following DP, particularly since the advent of reinforced staple technology. This study aims to determine if intraperitoneal drainage is necessary following DP. This study will compare groups using a composite endpoint of complications.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
234 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy: A Randomized Control Trial
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Dec 31, 2026
Anticipated Study Completion Date :
Jul 31, 2027

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Standard of care

Intraperitoneal drain will be placed near the pancreatic resection margin, which is the routine standard of care.

Device: 19 French Blake Drain
19 French Blake Intraperitoneal Drain will be placed near the pancreatic resection margin
Other Names:
  • Intraperitoneal drain
  • No Intervention: Omitting Standard of Care

    No intraperitoneal drain will be placed in the participants, which omits the routine standard of care.

    Outcome Measures

    Primary Outcome Measures

    1. Composite endpoint comparison [Within 90 days of surgery]

      Comparison between groups using a composite endpoint of complications that includes presence of Grade B POPF

    2. Composite endpoint comparison [Within 90 days of surgery]

      Comparison between groups using a composite endpoint of complications that includes presence of Grade C POPF

    3. Composite endpoint comparison [Within 90 days of surgery]

      Comparison between groups using a composite endpoint of complications that includes Readmission

    4. Composite endpoint comparison [Within 90 days of surgery]

      Comparison between groups using a composite endpoint of complications that includes presence of Organ Space Surgical Site Infection

    Secondary Outcome Measures

    1. Rates of endoscopic drainage vs percutaneous drainage of Grade B POPF [90-day post operative time point]

      Rates of drainage based off of the Grade B Postoperative pancreatic fistula

    2. Quality of Life Score [At day 14 postoperative]

      Post-operative Quality of Life score using the PROMIS-10 Global Health

    3. Quality of Life Score [At day 14 postoperative]

      Post-operative Quality of Life score using the PROMIS-10 Physical Function

    4. Quality of Life Score [At day 14 postoperative]

      Post-operative Quality of Life score using the original Drain Quality of Life scale

    5. Quality of Life Score [At day 90 postoperative]

      Post-operative Quality of Life score using the PROMIS-10 Global Health

    6. Quality of Life Score [At day 90 postoperative]

      Post-operative Quality of Life score using the PROMIS-10 Physical Function

    7. Quality of Life Score [At day 90 postoperative]

      Post-operative Quality of Life score using the original Drain Quality of Life scale

    8. Hospital Length of Stay [90-day post operative time point]

      Measurement of the difference in Hospital Length-of-Stay based on intraperitoneal drainage after DP

    9. Cost analysis for overall healthcare costs [At day 90 postoperative]

      Cost analysis for overall healthcare costs associated with both methods of postoperative care

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Subjects must be undergoing a scheduled distal pancreatectomy (with or without concurrent splenectomy)

    • Age ≥18 years

    • Subjects must have the ability to understand and the willingness to sign a written informed consent document.

    Exclusion Criteria:
    • Patients < 18 years old

    • Patients who are pregnant

    • Patients with a history of previous pancreatic surgery

    • Patients with a history of prior gastric resection, gastric bypass or sleeve gastrectomy

    • Patients with prior cystogastrostomy procedure

    • Patients who have failed prior endoscopic intervention or ultrasound due to esophageal or other gastrointestinal stricture

    • Patients with Type 3 or Type 4 Paraesophageal Hernia noted either on pre-operative imaging or intra-operatively

    • Patients undergoing concurrent resection of organs other than the pancreas or spleen

    • Patients who undergo oversewing of the pancreatic transection margin

    • Patients with unexpected intraoperative bleeding or adhesive disease which deem it unsafe to proceed without an intraabdominal drain

    • Patients who are unable to provide informed consent

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Case Comprehensive Cancer Center

    Investigators

    • Principal Investigator: Robert Simon, MD, Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Case Comprehensive Cancer Center
    ClinicalTrials.gov Identifier:
    NCT05720338
    Other Study ID Numbers:
    • CASE6222
    First Posted:
    Feb 9, 2023
    Last Update Posted:
    Feb 9, 2023
    Last Verified:
    Feb 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Case Comprehensive Cancer Center
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 9, 2023